PRME Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.2M
+34.8%
856.0K
+2.1%
838.0K
-31.6%
1.2M
+9.9%
1.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.2M
+34.8%
856.0K
+2.1%
838.0K
-31.6%
1.2M
+9.9%
1.1M
Operating Expenses
44.4M
-13.7%
51.5M
+4.2%
49.4M
-10.4%
55.2M
+1.3%
54.5M
R&D
33.4M
-2.1%
34.1M
-1.7%
34.7M
-21.1%
44.0M
+6.3%
41.4M
SG&A
11.0M
-36.6%
17.4M
+18.1%
14.7M
+31.5%
11.2M
-14.6%
13.1M
Operating Income
-43285000
+14.5%
-50654000
-4.2%
-48608000
+9.9%
-53973000
-1.1%
-53377000
EBITDA
-41500000
+15.0%
-48798000
-4.4%
-46732000
+10.3%
-52092000
-1.1%
-51513000
Net Income
-42109000
+14.3%
-49122000
-6.6%
-46079000
+8.9%
-50582000
+3.8%
-52591000
EPS (Basic)
$-0.24
+14.3%
$-0.28
-7.7%
$-0.26
+18.8%
$-0.32
+22.0%
$-0.41
EPS (Diluted)
$-0.24
+14.3%
$-0.28
-7.7%
$-0.26
+18.8%
$-0.32
+22.0%
$-0.41
Shares (Diluted)
177.2M
+0.1%
177.1M
+1.5%
174.5M
+8.7%
160.5M
+24.2%
129.2M
Prime Medicine (PRME) โ€” Financials